Literature DB >> 1711638

Cardioprotective effects of recombinant human extracellular-superoxide dismutase type C in rat isolated heart subjected to ischemia and reperfusion.

P O Sjöquist1, L Carlsson, G Jonason, S L Marklund, T Abrahamsson.   

Abstract

The cardioprotective effect of recombinant human extracellular-superoxide dismutase type C (rh-EC-SOD C) was studied in isolated perfused rat heart subjected to left coronary artery ligation for 30 or 60 min followed by 30-min reperfusion. A comparison was made with the effects of bovine CuZn-SOD. Reperfusion after 30-min coronary artery ligation was associated with a release of creatine kinase (CK) into the coronary effluent (71 +/- 5.2 IU/30 min), which was markedly reduced (39 +/- 5.5 IU/30 min) in hearts perfused with rh-EC-SOD C (28 mg/L). CuZn-SOD (4 or 20 mg/l) or a lower concentration of rh-EC-SOD C (5.6 mg/l) did not significantly attenuate CK outflow during reperfusion, however. In both vehicle- and SOD-treated hearts, the left ventricular developed pressure (LVDP) and the coronary flow recovered to 80-90% of baseline at the end of the reperfusion period. Increasing the ischemic period from 30 to 60 min caused a much more pronounced cardiac injury measured after 30-min reperfusion. In the hearts that received vehicle, recovery of LVDP (in percentage of baseline values) at the end of reperfusion was 58 +/- 2%, which was increased to 84 +/- 3 and 83 +/- 5% after treatment with rh-EC-SOD C (28 mg/L) and CuZn-SOD (20 mg/L), respectively. The corresponding values for recovery in coronary flow were 54 +/- 3% (vehicle), 69 +/- 4% (rh-EC-SOD C), and 74 +/- 3% (CuZn-SOD).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711638     DOI: 10.1097/00005344-199104000-00023

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  Nitric oxide homeostasis as a target for drug additives to cardioplegia.

Authors:  B K Podesser; S Hallström
Journal:  Br J Pharmacol       Date:  2007-05-08       Impact factor: 8.739

2.  Superoxide dismutase 3 limits collagen-induced arthritis in the absence of phagocyte oxidative burst.

Authors:  Tiina Kelkka; Juha Petteri Laurila; Outi Sareila; Peter Olofsson; Mikko Olavi Laukkanen; Rikard Holmdahl
Journal:  Mediators Inflamm       Date:  2012-03-05       Impact factor: 4.711

3.  Extracellular Superoxide Dismutase Expression in Papillary Thyroid Cancer Mesenchymal Stem/Stromal Cells Modulates Cancer Cell Growth and Migration.

Authors:  Alessia Parascandolo; Francesca Rappa; Francesco Cappello; Jaehyup Kim; David A Cantu; Herbert Chen; Gianluigi Mazzoccoli; Peiman Hematti; Maria Domenica Castellone; Marco Salvatore; Mikko O Laukkanen
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

4.  Cardiomyocyte-restricted overexpression of extracellular superoxide dismutase increases nitric oxide bioavailability and reduces infarct size after ischemia/reperfusion.

Authors:  Detlef Obal; Shujing Dai; Rachel Keith; Neviana Dimova; Justin Kingery; Yu-Ting Zheng; Jay Zweier; Murugesan Velayutham; Sumanth D Prabhu; Qianghong Li; Daniel Conklin; Dan Yang; Aruni Bhatnagar; Roberto Bolli; Gregg Rokosh
Journal:  Basic Res Cardiol       Date:  2012-10-26       Impact factor: 17.165

Review 5.  The role of Nrf2-mediated pathway in cardiac remodeling and heart failure.

Authors:  Shanshan Zhou; Wanqing Sun; Zhiguo Zhang; Yang Zheng
Journal:  Oxid Med Cell Longev       Date:  2014-07-01       Impact factor: 6.543

Review 6.  Extracellular Superoxide Dismutase: Growth Promoter or Tumor Suppressor?

Authors:  Mikko O Laukkanen
Journal:  Oxid Med Cell Longev       Date:  2016-05-12       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.